Maleic anhydride derivatives used as conjugation agents of anti-tumor agents on desired carriers
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 18, 1992
Grant Date -
N/A
app pub date -
Nov 28, 1989
filing date -
Nov 28, 1989
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention relates to anti-tumor-conjugation agent-protein compounds of the general formula I: ##STR1## wherein, R.sub.1 and R.sub.2 are each independently selected from hydrogen atom, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-6 carboxyalkyl, phenyl, or phenyl substituted by at least one of hydroxy, halogen, lower alkyl, lower alkoxy, or nitro, with the proviso that R.sub.1 and R.sub.2 cannot be simultaneously a hydrogen, and when one of R.sub.1 or R.sub.2 is a hydrogen, the other one cannot be --CH.sub.2 COOH; A is the residue of an anti-tumor agent containing at least one amino group available to form an amide bound; and B is a free .epsilon.-lysine containing residue selected from a peptide or a protein.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully